Perplexities of pertussis: Recent global epidemiological trends and their potential causes

Epidemiology and Infection

Volumn 142, Issue 4, 2014, Pages 672-684

  Jackson, D W ^a   Rohani, Pejman ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bordetella pertussis

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; DIPHTHERIA TOXOID; TETANUS TOXOID;

BACTERIAL IMMUNITY; BACTERIAL TRANSMISSION; BORDETELLA PERTUSSIS; DEMOGRAPHY; HUMAN; INCIDENCE; NONHUMAN; PERTUSSIS; POPULATION DYNAMICS; PREVALENCE; PREVENTIVE HEALTH SERVICE; REVIEW; SOCIOECONOMICS; TREND STUDY; VACCINATION; BACTERIAL GENETICS; BACTERIUM DETECTION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EVOLUTION; GEOGRAPHIC DISTRIBUTION; IMMUNITY; IMMUNIZATION; MASS COMMUNICATION; PATHOGEN LOAD; REVACCINATION; VACCINATION COMPOSITION; HEALTH; IMMUNOLOGY; MICROBIOLOGY;

BORDETELLA PERTUSSIS; HUMANS; PERTUSSIS VACCINE; POPULATION DYNAMICS; WHOOPING COUGH; WORLD HEALTH;

EID: 84901698221     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268812003093     Document Type: Review

References (81)

1. Varughese P. Incidence of pertussis in Canada. Canadian Medical Association Journal 1985; 132: 1041-1042.
2. Cherry JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clinical Infectious Diseases 1999; 28 (Suppl. 2): S107-111.
3. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clinical Microbiology Reviews 2005; 18: 326-382.
4. Crowcroft NS, et al. How best to estimate the global burden of pertussis? Lancet Infectious Diseases 2003; 3: 413-418.
5. Rohani P, Drake JM. The decline and resurgence of pertussis in the US. Epidemics 2011; 3: 183-188.
6. Moerman L, et al. The re-emergence of pertussis in Israel. Israel Medical Association Journal 2006; 8: 308-311.
7. Scheil W, et al. Pertussis in South Australia 1893 to 1996. Communicable Diseases Intelligence 1998; 22: 76-80.
8. Quinn H, McIntyre P. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bulletin of the World Health Organization 2011; 89: 666-674.
9. Gzyl A, et al. Pertussis in Poland. International Journal of Epidemiology 2004; 33: 358-365.
10. Bamberger ES, Srugo I. What is new in pertussis? European Journal of Pediatrics 2008; 167: 133-139.
11. Gangarosa EJ, et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 1998; 351: 356-361.
12. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatric Respiratory Reviews 2008; 9: 201-211.
13. World Health Organization (WHO). Immunization surveillance, assessment and monitoring (www.who.int/immunization-monitoring/data/data-subject/en/index. html). Accessed 27 August 2012.
14. European Commission. Health and Consumers Directorate- General Directorate C - Public Health and Risk Assessment C2 - Health information (http://ec.europa. eu/health/ph-information/dissemination/echi/docs/pertussis- en.pdf). Accessed 27 August 2012.
15. World Bank World Development Indicators (http://data.worldbank.org/data- catalog/world-developmentindicators). Accessed 31 August 2012.
16. Rohani P, Earn DJD, Grenfell BT. Opposite patterns of synchrony in sympatric disease metapopulations. Science 1999; 286: 968-971.
17. Broutin H, et al. Impact of vaccination and birth rate on the epidemiology of pertussis : a comparative study in 64 countries. Proceedings of the Royal Society of London, Series B: Biological Sciences 2010; 277: 3239-3245.
18. Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathogens 2009; 5: e1000647.
19. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatric Infectious Disease Journal 2003; 22: 22-27.
20. Clarkson JA, Fine PE. The efficiency of measles and pertussis notification in England and Wales. International Journal of Epidemiology 1985; 14: 153-168.
21. Doyle TJ, Glynn MK, Groseclose SL. Completeness of notifiable infectious disease reporting in the United States: an analytical literature review. American Journal of Epidemiology 2002; 155: 866-874.
22. Spokes PJ, Quinn HE, McAnulty JM. Review of the 2008-2009 pertussis epidemic in NSW: notifications and hospitalisations. New South Wales Public Health Bulletin 2010; 21: 167-173.
23. Crowcroft NS. Whooping cough - a continuing problem. British Medical Journal 2002; 324: 1537-1538.
24. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiology 2008; 3: 329-339.
25. Fine PE, Clarkson JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982; 1: 666-669.
26. Gay NJ, Miller E. Pertussis transmission in England and Wales. Lancet 2000; 355: 1553-1554.
27. Tanaka M, et al. Trends in pertussis among infants in the United States, 1980-1999. Journal of the American Medical Association 2003; 290: 2968-2975.
28. Campbell H, et al. Accelerating control of pertussis in England and Wales. Emerging Infectious Diseases 2012; 18: 38-47.
29. Cherry JD. Pertussis in adults. Annals of Internal Medicine 1998; 128: 64-66.
30. Rohani P, Earn DJD, Grenfell BT. Pertussis transmission in England and Wales - reply. Lancet 2000; 355: 1553-1554.
31. Nguyen HTH, Rohani P. Noise, nonlinearity and seasonality: the epidemics of whooping cough revisited. Journal of the Royal Society Interface 2008; 5: 403-413.
32. Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton, New Jersey: Princeton University Press, 2008.
33. Edwards KM, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96: 548-557.
34. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 2006; 367: 1926-1936.
35. Mooi FR. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerging Infectious Diseases 2009; 15: 1206-1213.
36. Clark TA, Messonnier NE, Hadler SC. Pertussis control : time for something new? Trends in Microbiology 2012; 20: 211-213.
37. Cherry JD. The present and future control of pertussis. Clinical Infectious Diseases 2010; 51: 663-667.
38. Sheridan SL, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. Journal of the American Medical Association 2012; 308: 454-456.
39. Versteegh FGA, Edwards KM. How to fight whooping cough? Archives of Pediatrics and Adolescent Medicine 2012; 166: 389-391.
40. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatric Infectious Disease Journal 2005; 24: S10-S18.
41. Shinall MC, et al. Potential impact of acceleration of the pertussis vaccine primary series for infants. Pediatrics 2008; 122: 1021-1026.
42. Fecsik AI. Studies on antibody production: XI. Variation in the secondary response as a function of the interval between two antigenic stimuli. Journal of Experimental Medicine 1964; 120: 1041-1049.
43. Blennow M, et al. Primary immunization of infants with an acellular pertussis vaccine in a doubleblind randomized clinical trial. Pediatrics 1988; 82: 293-299.
44. Taranger J, et al. Vaccination of infants with a fourdose and a three-dose vaccination schedule. Vaccine 1999; 18: 884-891.
45. Booy R, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 1992; 339: 507-510.
46. White JM, et al. The effect of an accelerated immunisation schedule on pertussis in England and Wales. Communicable Disease Report (CDR Review) 1996; 6: R86-91.
47. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21: 2003-2014.
48. Omer SB, et al. Nonmedical exemptions to school immunization requirements: Secular trends and association of state policies with pertussis incidence. Journal of the American Medical Association 2006; 296: 1757-1763.
49. Omer SB, et al. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. American Journal of Epidemiology 2008; 168: 1389-1396.
50. Anderson RM, May RM, McLean A. Possible demographic consequences of AIDS in developing countries. Nature 1988; 332: 228-234.
51. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford, New York: Oxford University Press, 1991.
52. Wendelboe AM, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatric Infectious Disease Journal 2005; 24: S58.
53. Lavine JS, Rohani P. Resolving pertussis immunity and vaccine efficiency using incidence time series. Expert Review of Vaccines (in press).
54. Rohani P, Zhong X, King AA. Contact network structure explains the changing epidemiology of pertussis. Science 2010; 330: 982-985.
55. Cherry JD, Baraff LJ, Hewlett E. The past, present, and future of pertussis. The role of adults in epidemiology and future control. Western Journal of Medicine 1989; 150: 319-328.
56. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clinical Infectious Diseases 1999; 28 (Suppl 2): S112-117.
57. Skoff TH, et al. Early impact of the US Tdap vaccination program on pertussis trends. Archives of Pediatrics and Adolescent Medicine 2012; 166: 344-349.
58. van Boven M, et al. Pathogen adaptation under imperfect vaccination: implications for pertussis. Proceedings of the Royal Society of London, Series B: Biological Sciences 2005; 272: 1617-1624.
59. Schellekens J, von Konig C-HW, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatric Infectious Disease Journal 2005; 24: S19-S24.
60. Lavine JS, King AA, Bjørnstad ON. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proceedings of the National Academy of Sciences USA 2011; 108: 7259-7264.
61. Aguas R, Gonçalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infectious Diseases 2006; 6: 112-117.
62. Cattaneo LA, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. Journal of Infectious Diseases 1996; 173: 1256-1259.
63. Mooi FR, van Loo IHM, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerging Infectious Diseases 2001; 7: 526-528.
64. Fry NK, et al. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infection and Immunity 2001; 69: 5520-5528.
65. Mooi FR, et al. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infection and Immunity 1998; 66: 670-675.
66. Borisova O, et al. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clinical and Vaccine Immunology 2007; 14: 234-238.
67. Advani A, et al. Appearance of Fim3 and ptxP3- Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine 2011; 29: 3438-3442.
68. Kodama A, et al. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. Journal of Clinical Microbiology 2004; 42: 5453-5457.
69. Mooi FR. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infection, Genetics and Evolution 2010; 10: 36-49.
70. Elomaa A, et al. Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories. Vaccine 2007; 25: 918-926.
71. Octavia S, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. Journal of Infectious Diseases 2012; 205: 1220-1224.
72. van Gent M, et al. Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS ONE 2012; 7: e46407.
73. Schmidtke AJ, et al. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerging Infectious Diseases 2012; 18: 1248-1255.
74. Bajardi P, et al. Human mobility networks, travel restrictions, and the global spread of 2009 H1N1 pandemic. PLoS ONE 2011; 6: e16591.
75. Russell CA, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008; 320: 340-346.
76. Shin SY, et al. Drug-resistant pandemic (H1N1) 2009, South Korea. Emerging Infectious Diseases 2011; 17: 702-704.
77. Wensing AM, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. Journal of Infectious Diseases 2005; 192: 958-966.
78. Wongsrichanalai C, Pickard AL. Epidemiology of drugresistant malaria. Lancet Infectious Diseases 2002; 2: 209-218.
79. Preston NW. Pertussis today. In: Wardlow AC, Parton R, eds. Pathogenesis and Immunity in Pertussis. Chichester, UK: John Wiley & Sons Ltd, 1988, pp. 1-19.
80. Blumenthal D, et al. Data withholding in genetics and the other life sciences : prevalences and predictors. Academic Medicine 2006; 81: 137-145.
81. Pisani E, et al. Time for fair trade in research data. Lancet 2010; 375: 703-705.